Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 5/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4499599 | 0.93 | NAMPT (0.53) | NAMPTTDP1TP53 | |
| SCHEMBL1377890 | 0.92 | NAMPT (0.53) | NAMPTTDP1SMN1; SMN2TP53MEN1 | |
| SCHEMBL1381498 | 0.89 | KCNJ1 (0.55) | NAMPTTDP1ALDH1A1TP53MEN1 | |
| SCHEMBL1379608 | 0.85 | TDP1 (0.45) | NAMPTTDP1ALDH1A1TP53MEN1 | |
| SCHEMBL1379247 | 0.85 | NAMPT (0.51) | NAMPTTDP1MAPT | |
| SCHEMBL1377354 | 0.84 | TP53 (0.51) | NAMPTTDP1SMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL1377872 | 0.84 | KDM4E (0.55) | NAMPTTDP1SMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL4498786 | 0.83 | NAMPT (0.53) | NAMPTTDP1SMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL1377858 | 0.83 | TP53 (0.51) | TDP1SMN1; SMN2ALDH1A1TP53NPC1 | |
| SCHEMBL1380451 | 0.82 | TP53 (0.51) | TDP1SMN1; SMN2ALDH1A1TP53NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521448-B2 | N-substituted benzimidazolyl c-Kit inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20060189629-A1 | N-substituted benzimidazolyl c-Kit inhibitors | OSI PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
| EP-1664021-A1 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005021531-A1 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189629-A1 | N-substituted benzimidazolyl c-Kit inhibitors | KIT, CHUK, TNNI3K | NAMPT 588/4885TDP1 3696/4885SMN1; SMN2 2900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.